S1EP15 Revolutionizing Treatment: Fenbendazole and Ivermectin's New Frontiers" cover art

S1EP15 Revolutionizing Treatment: Fenbendazole and Ivermectin's New Frontiers"

S1EP15 Revolutionizing Treatment: Fenbendazole and Ivermectin's New Frontiers"

Listen for free

View show details

About this listen

Got Questions? Send us a message!

Tune into "Fenben Voices" for "Revolutionizing Treatment: Fenbendazole and Ivermectin's New Frontiers." This episode discusses the repurposing of fenbendazole and ivermectin from veterinary use to promising cancer treatments. Dive into the narrative as we cover:

  • Potential of Fenbendazole and Ivermectin: Examining their mechanisms against cancer.
  • Legal and Ethical Landscape: The complexities of using experimental drugs in human medicine.
  • Patient Access and Right-to-Try Laws: How these laws affect patient access to these treatments.
  • Balancing Hope and Risk: The ethical considerations of offering experimental therapies to terminally ill patients.
  • The Future of Drug Repurposing: Prospects for fenbendazole and ivermectin in ongoing cancer research.

FenbendazoleHelp.org is an informational resource provided by the Fenben Foundation. The Fenben Foundation and its informational resources are not intended to provide personal medical advice. Always consult your physician before beginning any protocols. No information on this site is intended to diagnose, treat, or otherwise replace the opinion of medical professionals. The purpose of this site is for informational purposes ONLY.

What listeners say about S1EP15 Revolutionizing Treatment: Fenbendazole and Ivermectin's New Frontiers"

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.